Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Sorio, Guilherme Geraldo Lovato"'
Autor:
Arns, Beatriz, Sorio, Guilherme Geraldo Lovato, Vieceli, Tarsila, Pereira, Dariane, Celestino de Souza, Ândrea, Lamb Wink, Priscila, Paes, Julia Hoefel, David, Leonardo, Barboza, Fernanda, Hickmann, Stella, Alves, Gustavo, Santos, Antônio Cândido, da Rosa, Anelise, Duarte Alves, Marcelle, Massotti Magagnin, Cibele, Gomes, Eduardo, Zavascki, Alexandre Prehn, Rigatto, Maria Helena
Publikováno v:
In Journal of Global Antimicrobial Resistance March 2024 36:393-398
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Sorio, Guilherme Geraldo Lovato, Arns, Beatriz, Kawski, Cristiane Tejada da Silva, Gleit, Patricia Machado, Flores, Gabriela Pereira, Martins, Erik Menezes, Gorges, Muriel, Klafke, Renata Dortzbacher Feil, Alves, Marcelle Duarte, Magagnin, Cibele Massotti, Sampaio, Jorge Luiz Mello, Zavascki, Alexandre Prehn
Publikováno v:
Infection Control & Hospital Epidemiology; October 2023, Vol. 44 Issue: 10 p1686-1689, 4p
Autor:
Voysey, Merryn, Sprinz, Eduardo, Stein, Ricardo, Cunha, Debora Rosilei Miquini de Freitas, Silva, Larissa Pozzebon da, Santos, Thainá Garbino dos, Dias, Ana Luiza Perez Olive, Pinheiro, Jéssica Morgana Gediel, Sorio, Guilherme Geraldo Lovato, Vieira, Taiane Alves, Zambrano, Marina Bauer, Zimmer, Rafael Leal, Arns, Beatriz, Oxford COVID Vaccine Trial Group
Publikováno v:
Repositório Institucional da UFRGS
Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4–12 weeks. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3056::db91cb17f90ec4c5929899fcdbe102e0
Autor:
Voysey, Merryn, Sprinz, Eduardo, Stein, Ricardo, Cunha, Debora Rosilei Miquini de Freitas, Silva, Larissa Pozzebon da, Santos, Thainá Garbino dos, Dias, Ana Luiza Perez Olive, Pinheiro, Jéssica Morgana Gediel, Sorio, Guilherme Geraldo Lovato, Vieira, Taiane Alves, Zambrano, Marina Bauer, Zimmer, Rafael Leal, Arns, Beatriz, Oxford COVID Vaccine Trial Group
Publikováno v:
Repositório Institucional da UFRGS
Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAd
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3056::9399dea56f7583d6e00b21d1bbab347f